Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of COVID-19 Vaccine (Coronavirus vaccine - Generex Biotechnology)

Trial Profile

A clinical study of COVID-19 Vaccine (Coronavirus vaccine - Generex Biotechnology)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2020

At a glance

  • Drugs Coronavirus vaccine Generex Biotechnology (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Mar 2020 New trial record
    • 02 Mar 2020 According to an Generex Biotechnology Corporation media release, when the optimal vaccine formulation is determined, the company through NGIO intends to initiate the requisite clinical trials of the Ii-Key-nCOV peptide vaccine for approval in the United States.
    • 02 Mar 2020 According to an Generex Biotechnology Corporation media release, the parties activities under the Agreement, including the clinical trials, are subject to approval under China Technology Import Contract Management Regulations as well as the Chinese version of the FDA. The group plans to manufacture multi-valent Ii-Key peptide vaccines for evaluation in human clinical trials in China.

Trial Overview

Purpose

This study will evaluate COVID-19 Vaccine Using Ii-Key Peptide Vaccine Technology.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention -

Subjects

  • Subject Type volunteers
  • Sex male & female

Trial Details

Organisations

  • Affiliations Generex Biotechnology Corporation

Trial Dates

Other Details

  • Design multicentre; prospective
  • Phase of Trial Phase I
  • Location China; USA
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
Coronavirus vaccine Generex BiotechnologyPrimary Drug
-
-

Coronavirus vaccine

Trial History

Event Date Event Type Comment
09 Mar 2020 New trial record New trial record Updated 09 Mar 2020
02 Mar 2020 Other trial event According to an Generex Biotechnology Corporation media release, when the optimal vaccine formulation is determined, the company through NGIO intends to initiate the requisite clinical trials of the Ii-Key-nCOV peptide vaccine for approval in the United States. Updated 09 Mar 2020
02 Mar 2020 Other trial event According to an Generex Biotechnology Corporation media release, the parties activities under the Agreement, including the clinical trials, are subject to approval under China Technology Import Contract Management Regulations as well as the Chinese version of the FDA. The group plans to manufacture multi-valent Ii-Key peptide vaccines for evaluation in human clinical trials in China. Updated 09 Mar 2020
02 Mar 2020 Other trial event According to an Generex Biotechnology Corporation media release, the company has signed a contract from the Beijing Zhonghua Investment Fund Management Co., LTD. (an affiliate of China Technology Exchange), and Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD. to develop a COVID-19 vaccine using the Ii-Key peptide vaccine platform. Updated 09 Mar 2020

References

  1. Generex Biotechnology Corporation, Beijing Zhonghua Investment Fund Management Co., LTD. Generex Signs Contract with Chinese Partners Beijing Zhonghua Investment Fund Management Co., LTD and Sinotek-Advocates International Industry Development (Shenzhen) Co., Ltd. to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccine Technology. Media-Rel 2020;.

    Media Release
Back to top